Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gentamicin
Drug ID BADD_D01016
Description Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963.[A234349] It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by _Pseudomonas aeruginosa_.[A233325,A234359,A234364] There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams.[A234364] This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.[A234359,A234364] Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.[A234369]
Indications and Usage For treatment of serious infections caused by susceptible strains of the following microorganisms: P. aeruginosa, Proteus species (indole-positive and indole-negative), E. coli, Klebsiella-Enterobactor-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative).
Marketing Status Prescription; Discontinued
ATC Code D06AX07; J01GB03; S01AA11; S02AA14; S03AA06
DrugBank ID DB00798
KEGG ID D08013
MeSH ID D005839
PubChem ID 3467
TTD Drug ID D0L9UU
NDC Product Code 51662-1508; 63323-173
Synonyms Gentamicins | Gentamycins | Garamycin | Gentacycol | Gentamicin Sulfate | Sulfate, Gentamicin | Gentamicin Sulfate (USP) | Gentavet | Genticin | G-Myticin | G Myticin | GMyticin | Gentamicin | Gentamycin
Chemical Information
Molecular Formula C21H43N5O7
CAS Registry Number 1403-66-3
SMILES CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
NecrosisSodium/potassium-transporting ATPase subunit alpha-1P05023T408001647125; 1322021; 12905033; 2843053; 1315476; 2563204; 7694338; 11832431
Nephropathy toxicVariant-surface-glycoprotein phospholipase CP09194Not Available6092605; 6307156; 6276533; 3566282; 8663028; 3164751; 2623196; 7876334; 2159723; 8498544; 12039977
Renal impairmentDipeptidyl aminopeptidase-like protein 6P42658Not AvailableNot Available
Renal impairmentLysosomal Pro-X carboxypeptidaseP42785T20371Not Available
Toxicity to various agents1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1Q9NQ66T26846Not Available
Toxicity to various agentsPhospholipase A2P04054T31479Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Erythema23.03.06.0010.006884%Not Available
Extravasation08.01.03.008--Not Available
Eye irritation06.04.05.0030.001377%Not Available
Eye pain06.08.03.0020.002065%
Face oedema10.01.05.002; 08.01.07.003; 23.04.01.0040.002065%
Feeling abnormal08.01.09.014--Not Available
Fluid overload02.05.04.004; 14.05.06.001--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.0250.004819%
Gait disturbance17.02.05.016; 08.01.02.002--
Glomerular filtration rate decreased13.13.01.0090.001377%Not Available
Granulocytopenia01.02.03.003--Not Available
Haematoma24.07.01.0010.002065%
Haematuria24.07.01.047; 20.02.01.0060.001377%
Hallucination19.10.02.002--
Headache17.14.01.001--
Heart rate increased13.14.04.0020.001377%Not Available
Hepatic failure09.01.03.0020.000539%
Hepatic function abnormal09.01.02.0010.000359%Not Available
Hepatocellular injury09.01.07.0080.002754%Not Available
Hepatomegaly09.01.05.001--Not Available
Hyperkalaemia14.05.03.0010.002065%
Hyperpyrexia08.05.02.0020.001377%Not Available
Hypersensitivity10.01.03.0030.004819%
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023--Not Available
Hypocalcaemia14.04.01.004--
Hypokalaemia14.05.03.0020.003442%
Hypomagnesaemia14.04.02.001--
Hyponatraemia14.05.04.0020.001377%
Hypotension24.06.03.0020.015146%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 8 Pages